A U.S. biotechnology company has chosen to list its shares on the Hong Kong stock exchange before considering a Wall Street debut, highlighting a growing trend among global biotech firms to seek funding in Asia. The firm, whose name was not disclosed, is attracted by Hong Kong's expanding investor base and its close proximity to Chinese pharmaceutical partners. Many biotech companies are now turning to Hong Kong because of its favorable listing rules, which allow pre-revenue firms to go public. The city's deep capital markets and strong connections to the Chinese healthcare industry make it an appealing alternative to New York. By listing in Hong Kong first, the company hopes to access a pool of investors familiar with biotech and forge partnerships with Chinese drugmakers. The decision also reflects the broader shift of global biotech activity toward Asia, where demand for innovative medicines is rising quickly. A spokesperson for the firm said the move will help the company grow faster and tap into regional expertise. While Wall Street remains a long-term goal, the company believes starting in Hong Kong offers immediate strategic advantages. This is part of a larger pattern where more biotech firms look beyond traditional exchanges for their initial public offerings.